Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib + Imatinib in Advanced GIST
NCT06655246Phase 1Recruiting
- Sponsor
- Kura Oncology
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ziftomenib in gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Kura Oncology. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT06655246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655246.